NASDAQ:CBIO - Catalyst Biosciences Stock Price, Price Target & More

$26.63 -0.31 (-1.15 %)

(As of 04/25/2018 02:57 AM ET)

Previous Close$26.63

Today's Range$26.45 - $27.73

52-Week Range$3.11 - $37.00

Volume89,227 shs

Average Volume377,745 shs

Market Capitalization$324.93 million

P/E Ratio-3.57

Dividend YieldN/A

Beta2.51

About Catalyst Biosciences (NASDAQ:CBIO)

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that completed a Phase I clinical trials evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and coagulation activity in severe hemophilia A and B patients with inhibitors. The company also develops CB 2679d/ISU304, a Factor IX drug, which has completed preclinical studies for the prophylactic treatment of individuals with hemophilia B; and CB 2782, a pre-clinical anti-C3 protease program for the treatment of dry age-related macular degeneration. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis for development and manufacturing of the Factor IX products through Phase I/II clinical trials. The company has a strategic collaboration with Mosaic Biosciences to develop anti-C3 protease assets for dry age-related macular degeneration and other serious inflammatory retinal disorders. The company is headquartered in South San Francisco, California.

Receive CBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:CBIO

CUSIP87611R30

Webwww.catalystbiosciences.com

Phone650-266-8674

Debt

Debt-to-Equity RatioN/A

Current Ratio4.48%

Quick Ratio4.48%

Price-To-Earnings

Trailing P/E Ratio-3.57

Forward P/E Ratio-6.40

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.02 million

Price / Sales310.42

Cash FlowN/A

Price / CashN/A

Book Value$5.29 per share

Price / Book5.03

Profitability

EPS (Most Recent Fiscal Year)($7.45)

Net Income$-21,560,000.00

Net Margins-2,117.98%

Return on Equity-86.40%

Return on Assets-60.48%

Miscellaneous

Employees13

Outstanding Shares11,890,000

How to Become a New Pot Stock Millionaire

Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions

What is Catalyst Biosciences' stock symbol?

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?

Catalyst Biosciences shares reverse split before market open on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences (NASDAQ:CBIO) announced its quarterly earnings data on Thursday, March, 1st. The biopharmaceutical company reported ($0.96) EPS for the quarter, topping analysts' consensus estimates of ($1.41) by $0.45. The biopharmaceutical company earned $0.32 million during the quarter, compared to analyst estimates of $0.23 million. Catalyst Biosciences had a negative return on equity of 86.40% and a negative net margin of 2,117.98%. View Catalyst Biosciences' Earnings History.

When is Catalyst Biosciences' next earnings date?

Catalyst Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Catalyst Biosciences.

What price target have analysts set for CBIO?

3 brokerages have issued 1 year target prices for Catalyst Biosciences' shares. Their forecasts range from $11.00 to $75.00. On average, they anticipate Catalyst Biosciences' stock price to reach $45.00 in the next year. View Analyst Ratings for Catalyst Biosciences.

Who are some of Catalyst Biosciences' key competitors?

Some companies that are related to Catalyst Biosciences include Myovant Sciences (MYOV), G1 Therapeutics (GTHX), TherapeuticsMD (TXMD), Apellis Pharmaceuticals (APLS), Endo International (ENDP), WAVE Life Sciences (WVE), Theravance Biopharma (TBPH), PTC Therapeutics (PTCT), Mallinckrodt (MNK), Revance Therapeutics (RVNC), Dynavax Technologies (DVAX), Epizyme (EPZM), TG Therapeutics (TGTX), Retrophin (RTRX) and Intra-Cellular Therapies (ITCI).

Who are Catalyst Biosciences' key executives?

Catalyst Biosciences' management team includes the folowing people:

Dr. Nassim Usman Ph.D., Chief Exec. Officer, Pres and Director (Age 58)
Mr. Fletcher Payne, Chief Financial Officer (Age 55)
Dr. Howard Levy M.B.B.Ch., Ph.D., M.M.M., Chief Medical Officer (Age 64)
Dr. Charles S. Craik Ph.D., Co-Founder and Chairman of Scientific Advisory Board
Dr. Jack Nguyen Ph.D., Co-Founder

Has Catalyst Biosciences been receiving favorable news coverage?

Media stories about CBIO stock have trended positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Catalyst Biosciences earned a news impact score of 0.35 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 48.19 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Catalyst Biosciences?

Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalyst Biosciences' stock price today?

One share of CBIO stock can currently be purchased for approximately $26.63.

How big of a company is Catalyst Biosciences?

Catalyst Biosciences has a market capitalization of $324.93 million and generates $1.02 million in revenue each year. The biopharmaceutical company earns $-21,560,000.00 in net income (profit) each year or ($7.45) on an earnings per share basis. Catalyst Biosciences employs 13 workers across the globe.

How can I contact Catalyst Biosciences?

Catalyst Biosciences' mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-8674 or via email at [email protected]

MarketBeat Community Rating for Catalyst Biosciences (CBIO)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		126 (Vote Outperform)
Underperform Votes:		133 (Vote Underperform)
Total Votes:		259

MarketBeat's community ratings are surveys of what our community members think about Catalyst Biosciences and other stocks. Vote "Outperform" if you believe CBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Catalyst Biosciences (NASDAQ:CBIO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

3 Wall Street analysts have issued ratings and price targets for Catalyst Biosciences in the last 12 months. Their average twelve-month price target is $45.00, suggesting that the stock has a possible upside of 68.98%. The high price target for CBIO is $75.00 and the low price target for CBIO is $11.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$45.00	$45.00	$13.3333	$10.50
Price Target Upside:	68.98% upside	71.04% upside	27.11% upside	144.76% upside

Catalyst Biosciences (NASDAQ:CBIO) Consensus Price Target History

Price Target History for Catalyst Biosciences (NASDAQ:CBIO)

Catalyst Biosciences (NASDAQ:CBIO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/9/2018	B. Riley	Set Price Target	Buy -> Buy	$19.00 -> $49.00	High
2/9/2018	Chardan Capital	Boost Price Target	Buy -> Buy	$10.00 -> $75.00	High
6/6/2017	Ladenburg Thalmann	Initiated Coverage	Buy -> Buy	$11.00	Low
10/6/2016	HC Wainwright	Reiterated Rating	Buy	$52.50	N/A
6/30/2016	Rodman & Renshaw	Initiated Coverage	Buy	$52.50	N/A

(Data available from 4/25/2016 forward)

Catalyst Biosciences (NASDAQ:CBIO) Earnings History and Estimates Chart

Earnings by Quarter for Catalyst Biosciences (NASDAQ:CBIO)

Catalyst Biosciences (NASDAQ:CBIO) Earnings Estimates

2018 EPS Consensus Estimate: ($5.54)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($1.30)	($1.30)	($1.30)
Q2 2018	1	($1.32)	($1.32)	($1.32)
Q3 2018	1	($1.42)	($1.42)	($1.42)
Q4 2018	1	($1.50)	($1.50)	($1.50)

Catalyst Biosciences (NASDAQ CBIO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/9/2018		($1.15)					N/A
3/1/2018	Q4 2017	($1.41)	($0.96)	$0.23 million	$0.32 million	View	N/A
11/2/2017	Q3 2017		($1.34)		$0.32 million	View	N/A
8/3/2017	6/30/2017	($1.46)	($2.53)		$0.11 million	View	N/A
5/11/2017	3/31/2017	($5.14)	($4.57)		$0.27 million	View	N/A
3/8/2017	12/31/2016	($5.63)	($4.68)	$0.10 million	$0.10 million	View	N/A
11/3/2016	Q3	($0.46)	($0.40)	$0.10 million	$0.11 million	View	N/A
8/4/2016	Q216	($0.31)	($0.42)	$0.10 million	$0.11 million	View	N/A
5/5/2016	Q1 2016		($4.65)		$0.11 million	View	N/A
7/31/2015	Q2 2015		($10.49)			View	N/A
5/7/2015	Q1 2015		($20.98)		$0.06 million	View	N/A
11/5/2014	Q314	($0.22)	($0.14)		$0.03 million	View	Listen
8/6/2014	Q214	($0.33)	($0.24)		$0.04 million	View	Listen
5/7/2014	Q114	($0.37)	($0.44)	$3.54 million	$0.0870 million	View	Listen
2/13/2014	Q413	($0.39)	($0.40)	$0.59 million	$0.0930 million	View	Listen
11/5/2013	Q3 2013	($40.92)	($39.87)			View	N/A
8/6/2013	Q2 2013	($0.37)	($0.37)	$0.35 million		View	Listen
5/7/2013	Q1 2013	($0.34)	($0.24)	$600.00 million	$3.54 million	View	Listen
2/13/2013	Q4 2012	($0.31)	($0.47)	$0.83 million	$0.59 million	View	Listen
11/6/2012	Q312	($0.39)	($0.24)	$0.87 million	$0.77 million	View	N/A
8/7/2012		$0.39	$0.43			View	N/A
5/3/2012		($0.25)	$0.07			View	N/A
2/21/2012		($0.30)	($0.29)			View	N/A
11/1/2011		($0.20)	($0.27)			View	N/A
8/4/2011	Q2 2011	($22.03)	($7.66)			View	N/A
5/5/2011	Q1 2011	($14.69)	$43.44			View	N/A
2/10/2011	Q4 2010	($2.10)	($7.97)			View	N/A
11/4/2010	Q3 2010	($1.05)	$8.39			View	N/A
8/4/2010	Q2 2010	$22.03	$13.11			View	N/A
5/5/2010	Q1 2010	$15.74	$24.45			View	N/A
2/11/2010	Q4 2009	($36.72)	($100.82)			View	N/A
11/5/2009	Q3 2009	($12.59)	$5.25			View	N/A
8/5/2009	Q2 2009	($33.57)	($40.92)			View	N/A
5/11/2009	Q1 2009	($32.52)	($19.93)			View	N/A
2/12/2009	Q4 2008	($34.62)	($22.77)			View	N/A
11/6/2008	Q3 2008	($45.11)	($32.21)			View	N/A
8/5/2008	Q2 2008	($36.72)	($28.64)			View	N/A
5/6/2008	Q1 2008	($37.77)	($25.49)			View	N/A
2/12/2008	Q4 2007	($32.52)	($39.13)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Catalyst Biosciences (NASDAQ:CBIO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/4/2015		$0.5686		8/12/2015	8/14/2015	8/19/2015

(Data available from 1/1/2013 forward)

Catalyst Biosciences (NASDAQ CBIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 24.41%

Insider Trading History for Catalyst Biosciences (NASDAQ:CBIO)

Institutional Ownership by Quarter for Catalyst Biosciences (NASDAQ:CBIO)

Catalyst Biosciences (NASDAQ CBIO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/8/2018	James E Flynn	Insider	Sell	71,778	$30.53	$2,191,382.34
3/6/2018	James E Flynn	Major Shareholder	Sell	52,461	$30.87	$1,619,471.07
12/17/2015	Fletcher Payne	CFO	Buy	10,000	$2.00	$20,000.00
12/17/2015	Nassim Usman	CEO	Buy	4,000	$2.00	$8,000.00
12/17/2015	Stephen A Hill	Director	Buy	5,000	$2.03	$10,150.00	20,711
12/5/2013	Scott Sandell	major shareholder	Sell	1,000	$5.13	$5,130.00
11/21/2013	M James Barrett	major shareholder	Sell	5,333	$5.16	$27,518.28
5/10/2013	Julia R Brown	Director	Buy	6,000	$5.09	$30,540.00
3/11/2013	Stephen A Hill	CEO	Buy	20,000	$4.43	$88,600.00
11/16/2012	Bvf Partners L P/Il	Major Shareholder	Buy	595,000	$4.00	$2,380,000.00
11/8/2012	Bvf Partners L P/Il	Major Shareholder	Buy	72,429	$4.03	$291,888.87
11/2/2012	Bvf Partners L P/Il	Major Shareholder	Buy	139,700	$4.05	$565,785.00

(Data available from 1/1/2013 forward)

Catalyst Biosciences (NASDAQ CBIO) News Headlines

Source:

Date	Headline
	Catalyst Biosciences Announces Presentation at the 2018 Association for Research in Vision and Ophthalmology Annual Meeting finance.yahoo.com - April 23 at 8:11 AM
	Catalyst Biosciences (CBIO) Receives Average Rating of "Buy" from Analysts www.americanbankingnews.com - April 23 at 3:18 AM
	Catalyst Biosciences (CBIO) Raised to Buy at BidaskClub www.americanbankingnews.com - April 21 at 7:06 AM
	3 Things In Biotech, April 14: Organovo, Catalyst, And Aeglea Open Up seekingalpha.com - April 15 at 9:05 AM
	Initiation of Phase 2b Trial on Track for Q3 2018 globenewswire.com - April 12 at 8:25 AM
	Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B finance.yahoo.com - April 12 at 8:25 AM
	Catalyst Biosciences (CBIO) Downgraded to "Hold" at BidaskClub www.americanbankingnews.com - March 29 at 11:17 AM
	Catalyst Biosciences Inc (CBIO) Given Average Rating of "Buy" by Brokerages www.americanbankingnews.com - March 29 at 5:18 AM
	Zacks: Analysts Set $57.00 Price Target for Catalyst Biosciences Inc (CBIO) www.americanbankingnews.com - March 28 at 9:59 AM
	Catalyst Biosciences (CBIO) Reports $1.5 MillionMilestone Payments for Neuronal Nicotinic Receptor (NNR) Asset www.streetinsider.com - March 26 at 5:23 PM
	Catalyst Biosciences Receives $1.5 Million In Two Milestone Payments for Neuronal Nicotinic Receptor (NNR) Asset finance.yahoo.com - March 26 at 8:16 AM
	Catalyst Biosciences (CBIO) Lifted to "Sell" at ValuEngine www.americanbankingnews.com - March 25 at 8:10 PM
	Catalyst Biosciences to Present at The Needham and Company 17th Annual Healthcare Conference - GlobeNewswire (press release) globenewswire.com - March 19 at 8:16 AM
	Catalyst Biosciences to Present at The Needham and Company 17th Annual Healthcare Conference finance.yahoo.com - March 19 at 8:16 AM
	Financial Survey: Catalyst Biosciences (CBIO) versus Avid Bioservices (CDMO) www.americanbankingnews.com - March 12 at 9:14 PM
	Analysts Set $57.00 Target Price for Catalyst Biosciences Inc (CBIO) www.americanbankingnews.com - March 10 at 3:22 PM
	Zacks.com featured highlights include: Unisys, Catalyst, Liberty and New Mountain finance.yahoo.com - March 9 at 8:14 AM
	Catalyst Biosciences Inc (CBIO) Major Shareholder Sells $1,619,471.07 in Stock www.americanbankingnews.com - March 8 at 6:13 PM
	Catalyst Biosciences Inc (CBIO) Insider Sells $2,191,382.34 in Stock www.americanbankingnews.com - March 8 at 6:13 PM
	Stock Traders Purchase High Volume of Put Options on Catalyst Biosciences (CBIO) www.americanbankingnews.com - March 8 at 8:04 AM
	Catalyst Biosciences to Present at The Cowen and Company 38th Annual Health Care Conference - GlobeNewswire (press release) globenewswire.com - March 7 at 8:12 AM
	Catalyst Biosciences to Present at The Cowen and Company 38th Annual Health Care Conference finance.yahoo.com - March 7 at 8:12 AM
	Investors Purchase Large Volume of Call Options on Catalyst Biosciences (CBIO) www.americanbankingnews.com - March 7 at 7:26 AM
	Catalyst Biosciences (CBIO) & Mediwound (MDWD) Head-To-Head Comparison www.americanbankingnews.com - March 4 at 1:10 AM
	Analysts Anticipate Catalyst Biosciences Inc (CBIO) to Announce ($1.30) Earnings Per Share www.americanbankingnews.com - March 2 at 7:12 PM
	Catalyst Biosciences Reports Fourth Quarter and Full-Year 2017 Operating & Financial Results and Provides Corporate Update finance.yahoo.com - March 1 at 5:56 PM
	Catalyst Biosciences (CBIO) Reports Manufacturing Agreement with AGC Biologics - StreetInsider.com www.streetinsider.com - February 27 at 8:14 AM
	Catalyst Biosciences (CBIO) Set to Announce Earnings on Tuesday www.americanbankingnews.com - February 27 at 2:16 AM
	Catalyst Biosciences Announces Manufacturing Agreement with AGC Biologics for Subcutaneous Factor IX Product CB 2679d finance.yahoo.com - February 26 at 5:48 PM
	Catalyst Biosciences Announces Closing of Public Offering of ... - GlobeNewswire (press release) globenewswire.com - February 16 at 8:14 AM
	Catalyst Biosciences Inc (CBIO) Receives Average Rating of "Strong Buy" from Brokerages www.americanbankingnews.com - February 14 at 7:18 PM
	Catalyst Biosciences Inc (CBIO) to Post FY2017 Earnings of ($7.85) Per Share, B. Riley Forecasts www.americanbankingnews.com - February 14 at 6:10 AM
	Catalyst Biosciences Inc Expected to Earn FY2022 Earnings of $2.70 Per Share (CBIO) www.americanbankingnews.com - February 13 at 4:52 PM
	Catalyst Biosciences (CBIO) On Phase 1/2 clinical trial evaluating subcutaneous administration of hemophilia B candidate CB 2679d/ISU304 - Slideshow seekingalpha.com - February 12 at 3:41 PM
	Analysts Set $36.08 Price Target for Catalyst Biosciences Inc (CBIO) www.americanbankingnews.com - February 10 at 9:34 PM
	Chardan Capital Boosts Catalyst Biosciences (CBIO) Price Target to $75.00 www.americanbankingnews.com - February 10 at 1:26 PM
	Analyst Lifts Catalyst Biosciences PT From $10 To $75 On Hemophilia B Product finance.yahoo.com - February 10 at 9:10 AM
	Catalyst Biosciences (CBIO) PT Set at $19.00 by B. Riley www.americanbankingnews.com - February 9 at 9:30 PM
	Catalyst Biosciences Announces Positive Top-Line Data from Phase 1/2 Study of Subcutaneous CB 2679d/ISU304 in Individuals with Hemophilia B finance.yahoo.com - February 9 at 9:21 AM
	Catalyst Biosciences (CBIO) Given Buy Rating at B. Riley www.americanbankingnews.com - February 1 at 2:54 PM
	Catalyst Biosciences to Present Multi-Dose Subcutaneous Data for CB 2679d in Individuals with Hemophilia B in an Oral Presentation at the 11th Annual Congress of EAHAD finance.yahoo.com - January 31 at 3:39 PM
	Comparing Catalyst Biosciences (CBIO) and Cardiome Pharma (CRME) www.americanbankingnews.com - January 30 at 3:18 AM
	Catalyst Biosciences Inc (CBIO) Given Consensus Rating of "Strong Buy" by Brokerages www.americanbankingnews.com - January 24 at 7:06 PM
	Brokerages Set $14.42 Target Price for Catalyst Biosciences Inc (CBIO) www.americanbankingnews.com - January 8 at 10:06 PM
	Catalyst Biosciences (CBIO) Commences Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia ... - StreetInsider.com www.streetinsider.com - January 5 at 9:18 AM
	Catalyst Biosciences (CBIO) Commences Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B with Inhibitors www.streetinsider.com - January 4 at 5:35 PM
	Catalyst Biosciences Initiates Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B with Inhibitors finance.yahoo.com - January 4 at 9:11 AM
	Catalyst Biosciences (CBIO) Rating Increased to Buy at Zacks Investment Research www.americanbankingnews.com - January 2 at 10:34 PM
	Zacks Investment Research Lowers Catalyst Biosciences (CBIO) to Hold www.americanbankingnews.com - January 1 at 6:54 PM
	Catalyst Biosciences Announces Closing of Public Offering of Common Stock - GlobeNewswire (press release) globenewswire.com - December 23 at 6:08 AM

Catalyst Biosciences (NASDAQ:CBIO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Catalyst Biosciences (NASDAQ:CBIO) Income Statement, Balance Sheet and Cash Flow Statement

Catalyst Biosciences (NASDAQ CBIO) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff